Terns Pharmaceuticals, Inc. (NASDAQ:TERN) presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated patients with chronic myelogenous leukemia (CML) at the American Society of Hematology Annual Meeting and Exposition on Monday. By the cut-off date of September 13, 2025, 63 patients were enrolled. Facts Of the 38 efficacy-evaluable patients, […]
